Cabaletta Bio, Inc. CABA
1.28 USD -0.14 (-10.00%)
Nov 5, 2026, 3:19 PM EST
1.19 Day range 1.43
1.19 52-week range 4.23
- YTD
- -41.64%
- 1 year
- -51.03%
News
benzinga.com Cabaletta Bio Q3 EPS $(0.28) Beats $(0.33) Estimate Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 15.15 percent. This is a 36.36 percent increase over losses of…
globenewswire.com Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2…
globenewswire.com Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
globenewswire.com Cabaletta Bio to Participate in Upcoming Investor Conferences PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
seekingalpha.com Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase…
globenewswire.com Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
seekingalpha.com Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
benzinga.com Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted…
globenewswire.com Cabaletta Bio to Participate in Upcoming Investor Conferences PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
benzinga.com Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3 Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.- benzinga.com Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of…
globenewswire.com Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
seekingalpha.com Cabaletta Bio: The Market Sold The EULAR News, I'm Buying Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing…
seekingalpha.com Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
benzinga.com Cabaletta Bio Presents New Clinical Data Supporting Rese-Cel As Potential Treatment For Multiple Autoimmune Diseases, At EULAR 2026 Congress 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through…
globenewswire.com Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through…
zacks.com Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
zacks.com Cabaletta Bio (CABA) Upgraded to Buy: Here's Why Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.- benzinga.com Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4 Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.
seekingalpha.com Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress. Key catalysts include registrational trials for rese-cel in…- benzinga.com Cabaletta Bio Q1 EPS $(0.39), Inline Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same…
globenewswire.com Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV study presented today at ASGCT 2026 Annual Meeting along with initial…
globenewswire.com Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like…- benzinga.com Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.
benzinga.com Cabaletta Prices Share Sale Of 51.73M Shares at $2.90 to Fund Autoimmune Therapy Development Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for…
globenewswire.com Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative…
businesswire.com Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply…
globenewswire.com Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial…
benzinga.com Cabaletta Bio Doses First Two Patients Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET™ clinical…
benzinga.com FGI Industries, Nouveau Monde Graphite And Other Big Stocks Moving Lower In Friday's Pre-Market Session Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29 cents per share beating estimates but sales missing. Stock down 7.8% in pre-market. Other stocks…
benzinga.com Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock.- benzinga.com Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13 Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.
benzinga.com Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16 Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.
benzinga.com Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 13.98 percent. This is a 38.46 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket - benzinga.com Cabaletta Bio Announces 2026 Strategic Priorities To Advance Rese-Cel Toward 2027 BLA, Expand Automated Cellares Manufacturing, And Progress RESET Trials Across Autoimmune Diseases Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment…
benzinga.com FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30 Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $15 to $30.
- benzinga.com Cabaletta Bio Announces Clinical Data And Development Updates Across RESET-Myositis, RESET-SSc And RESET-SLE Trials Evaluating Rese-Cel – All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
- benzinga.com Cabaletta Bio Reports Initial Results For Rese-cel In Pemphigus Vulgaris Without Preconditioning; Shows Complete B Cell Depletion, Rapid Reduction In Autoantibodies And Near-complete Resolution Of Clinical Symptoms In Two Of Three Refractory Patients – Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators…
- benzinga.com Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $15 Price Target Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $15 price target.
benzinga.com Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.